|The bicalutamide Early Prostate Cancer Program. Demography|
|Reviewers: Li Liu, MD|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Authors: See WA, McLeod D, Iversen P, et al.
It has been well established that addition of adjuvant hormonal therapy to local definitive therapy significantly improves local tumor control, disease-free survival, and overall survival in patients with locally advanced adenocarcinomas of the prostate (Int J Radiat Oncol Biol Phys 2001 Mar 15; 49(4): 937-46; N Engl J Med 1997 Jul 31;337(5):295-300). However, the use of hormone therapy in patients with early stage prostate cancer remains undefined. In this study, the researchers reported demographic data of 3 randomized, double-blind, placebo-controlled trials evaluating whether the addition of bicalutamide (Casodex) is beneficial in patients with localized prostate cancer.
These are the largest randomized clinical trials of Casodex for patients with localized prostate cancer. These studies were designed to find out whether the addition of Casodex 150 mg to standard care reduces the risk of disease progression and improves survival. The final results of these studies are anxiously awaited so the important question of hormonal use in early stage prostate cancer is definitively answered.